Elevated Aβ42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AβPP metabolism

American Journal of Pathology

Volumn 156, Issue 3, 2000, Pages 797-805

  Kuo, Yu Min ^a   Kokjohn, Tyler A ^b   Watson, M Desiree ^c   Woods, Amina S ^d   Cotter, Robert J ^d   Sue, Lucia I ^a   Kalback, Walter M ^a   Emmerling, Mark R ^c   Beach, Thomas G ^a   Roher, Alex E ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

^c PFIZER INC   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN; ENZYME IMMUNOASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOLATION AND PURIFICATION; MALE; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; PATHOLOGY; TEMPORALIS MUSCLE; WESTERN BLOTTING; ADULT; AGE; BRAIN BLOOD VESSEL; CONTROLLED STUDY; HUMAN TISSUE; MUSCLE LEVEL; PARENCHYMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN METABOLISM;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BLOTTING, WESTERN; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MASS SPECTROMETRY; MIDDLE AGED; PEPTIDE FRAGMENTS; TEMPORAL MUSCLE;

EID: 0033622195     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64947-4     Document Type: Article

References (48)

1. Normal and abnormal biology of the β-amyloid precursor protein
2. Amyloid β-protein deposition in tissues other than brain in Alzheimer's disease
3. Expression of β amyloid protein precursor mRNAs: Recognition of a novel alternatively spliced form and quantitation in Alzheimer's disease using PCR
4. Secretion of Alzheimer's disease Aβ amyloid peptide by activated human platelets
5. Human neutrophil phagocytic granules contain a truncated soluble form of the Alzheimer β/A4 amyloid precursor protein (APP)
6. Localization of Alzheimer βA4 amyloid precursor protein at central and peripheral synaptic sites
7. Aβ 42 is the predominant form of amyloid β-protein in the brains of short-term survivors of head injury
8. Traumatic brain injury increases β-amyloid peptide 1-42 in cerebrospinal fluid
9. Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer's amyloid β
10. High levels of circulating β-amyloid peptide do not cause cerebral β-amyloidosis in transgenic mice
11. Sporadic inclusion-body myositis and its similarities to Alzheimer disease brain: Recent approaches to diagnosis and pathogenesis, and relation to aging
12. Increased plasma amyloid β protein 1-42 levels in Down syndrome
13. Making the diagnosis of Alzheimer's disease: A primer for practicing pathologists
14. Frequency of stages of Alzheimer-related lesions in different age categories
15. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report cf the consortium on DLB international workshop
16. Preliminary NINDS neuropathologic criteria for Steele-Richardson- Olszewski syndrome (progressive supranuclear palsy)
17. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders
18. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal
19. Regional differences in fibre type composition in the human temporalis muscle
20. Basic reactions of muscle
21. High levels of circulating Aβ42 are sequestered by plasma proteins in Alzheimer disease
22. Perfusion-fixation of the human brain for immunohistochemistry: Comparison with immersion-fixation
23. Soluble amyloid peptide concentration as a predictor of synaptic change in Alzheimer's diseases
24. Structural alterations in the peptide backbone of β-amyloid core protein may account for its deposition and stability in Alzheimer's disease
25. Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains
26. Isolation and quantification of soluble Aizheimer's β-peptide from biological fluids
27. Alzheimer's soluble amyloid β is a normal component of human urine
28. Molecular pathology of amyloidogenic proteins and the role of vascular amyloidosis in Alzheimer's disease
29. Blood-brain barrier transport of circulating Alzheimer's amyloid β
30. Plasma amyloid β-peptide 1-42 and incipient Alzheimer's disease
31. Glycoprotein 330/megalin: Probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid β at the blood-brain and blood-cerebrospinal fluid barriers
32. Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid β peptide in aged squirrel monkey with cerebral amyloid angiopathy
33. Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders
34. Head trauma and the risk of Alzheimer's disease
35. Atherosclerosis, apolipoprotein E, and prevalence of dementia, and Alzheimer's disease in the Rotterdam Study
36. 15-year Longitudinal study of blood pressure and dementia
37. Brain infarction and the clinical expression of Alzheimer disease: The Nun Study
38. Transport of human β-amyloid peptide through the rat blood-brain barrier after global cerebral ischemia
39. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease
40. Apolipoprotein E genotype, and amyloid load in Alzheimer disease, and control brains
41. Aβ peptide length and apolipoprotein E genotype in Alzheimer's disease
42. Aβ1-40 but not Aβ1-42 levels in cortex correlate with apolipoprotein E ε4 allele dosage in sporadic Alzheimer's disease
43. Preferential deposition of amyloid β protein (Aβ) in the form Aβ40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E ε4 allele
44. β-Amyloid precursor protein: Location of transmembrane domain and specificity of δ-secretase cleavage
45. Mechanism of the cleavage specificity of Alzheimer's disease γ-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein
46. Amyloid, the presenilins, and Alzheimer's disease
47. Endogenous proteins controlling amyloid β-peptide polymerization: Possible implications for β-amyloid formation in the central nervous system and in peripheral tissues
48. Amyloid β-peptide is transported on lipoproteins, and albumin in human plasma